A study was conducted by Dr Akiyama & associates from the Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka in Japan to evaluate the treatment effect of topical unoprostone isopropyl (unoprostone) (in the form of eye drops) on patients with retinitis pigmentosa (RP). This medication is currently used in glaucoma.
Forty patients with typical forms of RP were included in the study, out of which 17 patients were treated with 0.12% topical unoprostone twice daily in a randomly selected eye. The efficacy of the treatment was monitored by visual acuity and visual field testing using the Humphrey Field Analyzer (HFA). In addition, 12 RP patients who were included this study and 12 normal subjects were evaluated in terms of their macular blood flow of both eyes after instillation of unoprostone using the laser speckle method.
Retina India is a not-for-profit organization, registered with the Charity Commissioner, Mumbai, India, established for empowering people with retinal disorders, and bringing them and their families on a common platform with physicians, researchers, counselors, low vision and mobility experts and other specialists.
Wednesday, July 23, 2014
Is Valproic Acid effective in treating patients with Retinitis Pigmentosa?
There have been some reports in academic journals about the use of Valproic acid (VPA) in Retinitis Pigmentosa (RP). We thought we can review the current status of these trials and evaluate where we stand in the outcomes.
Tuesday, July 22, 2014
Is docosahexaenoic Acid (DHA) effective as treatment for patients with X-Linked Retinitis Pigmentosa?
X-linked retinitis pigmentosa is a severe inherited retinal degenerative disease with a frequency of 1 in 100,000 persons. Because no cure is available for this orphan disease and treatment options are limited, slowing of disease progression is considered to be a meaningful outcome.
A study was conducted in Dallas, Texas, at the Retina Foundation of the Southwest, and others, to determine whether high-dose docosahexaenoic acid (DHA), an ω-3 polyunsaturated fatty acid, slows progression of X-linked retinitis pigmentosa as measured by cone electroretinography (ERG).
A study was conducted in Dallas, Texas, at the Retina Foundation of the Southwest, and others, to determine whether high-dose docosahexaenoic acid (DHA), an ω-3 polyunsaturated fatty acid, slows progression of X-linked retinitis pigmentosa as measured by cone electroretinography (ERG).
Iodine supplement may limit or reduce extent of macular thicking in patients with Retinitis Pigmentosa
Current treatments for cystoid macular edema (CME) in retinitis pigmentosa (RP) are not always effective, may lead to adverse effects, and may not restore visual acuity. The present research lays the rationale for evaluating whether an iodine supplement could reduce CME in RP.
A study was orgnized at the Berman-Gund Laboratory for the Study of Retinal Degenerations, in the Department of Ophthalmology at Harvard Medical School, Massachusetts Eye and Ear Infirmary (MEEI) in Boston, to determine whether central foveal thickness (CFT) in the presence of CME is related to dietary iodine intake, which was inferred from urinary iodine concentration (UIC) in nonsmoking adults with RP.
A study was orgnized at the Berman-Gund Laboratory for the Study of Retinal Degenerations, in the Department of Ophthalmology at Harvard Medical School, Massachusetts Eye and Ear Infirmary (MEEI) in Boston, to determine whether central foveal thickness (CFT) in the presence of CME is related to dietary iodine intake, which was inferred from urinary iodine concentration (UIC) in nonsmoking adults with RP.
Subscribe to:
Posts (Atom)